Endpoints News
Beam looks to accelerated approval for AATD base editing after promising update
Beam Therapeutics has provided a much-awaited update on its therapy that uses a form of CRISPR called base editing to precisely fix a single genetic typo responsible for a rare genetic disease.
On Wednesday,